Abstract

Klonoff et al recently described a new glucose meter error grid.
1
This error grid updates the limits for the various zones that contain clinically significant glucose meter errors. To determine these limits, clinicians were provided scenarios and were asked to describe glucose error levels that would prompt them to treat patients in several ways ranging from no treatment to emergency treatment. One could view this exercise as clinicians responding to a patient’s symptoms, or the threat of
Diabetic retinopathy is an example of serious chronic injury to patients with diabetes. Hemoglobin A1c levels that exceed 5.5% are associated with diabetic retinopathy. 2 Yet an A1c level of 5.5% is equivalent to a mean glucose of 111 mg/dL. 3 In error grid terms, a meter measuring glucose with a true level of 111 mg/dL, but reading 100 mg/dL, demonstrates an error in the A zone, which is the no-treatment-needed zone (this is the case for all of the popular glucose error grids including Clarke, 4 Parkes, 5 as well as the new surveillance error grid 1 ). To be fair, the 5.5% level of A1c is the starting point for diabetic retinopathy but for an A1c level of 6.5% (equivalent to a mean glucose of 140 mg/dL), the prevalence of diabetic retinopathy doubles to 20%, yet this level of glucose bias is still in the A zone.
One might argue that the possibility of a 10% to 40%
Clearly one needs to inform about allowable glucose meter deviations associated with the treatment of acute injury and the proposed error grid does that superbly. We propose that another error grid is needed to inform about diabetes complications by providing allowable error limits for long-term bias. This situation has analogies in other areas such as preventive cardiology. An assay such as low density lipoprotein (LDL) cholesterol, which is not used to diagnose acute injury, might have limits set for allowable long-term bias to inform about the risk of coronary events associated with an incorrect LDL measurement.
Footnotes
Abbreviation
LDL, low density lipoprotein.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.
